Citation: | REN Ying, HE Yu, LI Ping. A study on the correlation between FGFR3 and TERT gene mutations and the pathological grade of urethral epithelial carcinoma[J]. Chinese Journal of General Practice, 2025, 23(2): 219-222. doi: 10.16766/j.cnki.issn.1674-4152.003871 |
[1] |
周晓蝶, 陈巍魏, 余波, 等. 尿路上皮癌的临床病理学特征[J]. 诊断学理论与实践, 2023, 22(3): 292-299.
ZHOU X D, CHEN W W, YU B, et al. Clinicopathological features of urothelial carcinoma[J]. Diagnostic theory and practice, 2023, 22(3): 292-299.
|
[2] |
BAROCAS D A, BOORJIAN S A, ALVAREZ R D, et al. Microhematuria: AUA/SUFU guideline[J]. J Urol, 2020, 204(4): 778-786.
|
[3] |
BERTZ S, STOHR R, GAISA N T, et al. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder[J]. Histopathology, 2020, 77(6): 949-962.
|
[4] |
薛立芝, 谭焕腾, 张思泉, 等. 成纤维细胞生长因子21在2型糖尿病视网膜病变患者血清中的水平及其临床意义[J]. 中华全科医学, 2020, 18(6): 959-961. doi: 10.16766/j.cnki.issn.1674-4152.001402
XUE L Z, TAN H T, ZHANG S Q, et al. The level of serum fibroblast growth factor 21 in patients with type 2 diabetic retinopathy and its clinical significance[J]. Chinese Journal of General Practice, 2020, 18(6): 959-961. doi: 10.16766/j.cnki.issn.1674-4152.001402
|
[5] |
龙慧民, 项卓仪. 转移性尿路上皮癌的药物治疗研究进展[J]. 浙江医学, 2021, 43(17): 1824-1829, 1845.
LONG H M, XIANG Z Y. Advances in drug therapy for metastatic urothelial carcinoma[J]. Zhejiang Medical Journal, 2021, 43(17): 1824-1829, 1845.
|
[6] |
张晶镔, 王文萍. 血清25羟维生素D与气阴两虚2型糖尿病合并甲状腺结节TI-RADS分级相关性分析[J]. 辽宁中医药大学学报, 2024, 26(5): 163-166.
ZHANG J B, WANG W P. Correlation analysis between serum 25-hydroxyvitamin D and TI-RADS grade of thyroid nodules in type 2 diabetes mellitus with deficiency of both qi and yin[J]. Journal of Liaoning University of Traditional Chinese Medicine, 2024, 26(5): 163-166.
|
[7] |
胡文豪, 黄佳. miR-615-3p通过靶向HMGB3促进膀胱癌的转移[J]. 中国卫生检验杂志, 2021, 31(21): 2575-2580.
HU W H, HUANG J. miR-615-3p promotes the metastasis of bladder cancer by targeting HMGB3[J]. Chinese Journal of Health Inspection, 2021, 31(21): 2575-2580.
|
[8] |
BROOKS N A, KOKOROVIC A, XIAO L, et al. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus calmette-cuerin[J]. BJU International, 2020, 128(1): 65-71.
|
[9] |
沈丹. DKK1在膀胱癌组织中表达水平与预后的相关性[J]. 中国卫生检验杂志, 2022, 32(7): 839-841.
SHEN D. The correlation between the expression level of Shendan DKK1 in bladder cancer tissues and prognosis[J]. Chinese Journal of Health Inspection, 2022, 32(7): 839-841.
|
[10] |
HUA R, LI Q, GAO H, et al. Association of human telomerase reverse transcriptase promoter mutation with unfavorable prognosis in glioma: a systematic review and meta-analysis[J]. J Res Med Sci, 2023, 28: 47. DOI: 10.4103/jrms.jrms_371_22.
|
[11] |
YANG R, HAN Y, GUAN X, et al. Regulation and clinical potential of telomerase reverse transcriptase (TERT/hTERT) in breast cancer[J]. Cell Commun Signal, 2023, 21(1): 218.
|
[12] |
SUN S, WANG Y, LIU Y, et al. Telomerase reverse transcriptase gene polymorphisms and cervical cancer susceptibility in high-risk human papillomavirus-infected women[J]. J Obstet Gynaecol Res, 2024, 50(1): 95-102.
|
[13] |
BATISTA R, LIMA L, VINAGRE J, et al. TERT promoter mutation as a potential predictive biomarker in BCG-Treated bladder cancer patients[J]. Int J Mol Sci, 2020, 21(3): 947.
|
[14] |
曾平, 郭鹏翔, 骆横. 人端粒酶逆转录酶在肿瘤转录调控机制中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(1): 68-72.
ZENG P, GUO P X, LUO H. Research progress of human telomerase reverse transcriptase in tumor transcriptional regulation mechanism[J]. Journal of Applied Oncology, 2023, 37(1): 68-72.
|
[15] |
DRATWA M, WYSOCZANSKA B, TURLEJ E, et al. Heterogeneity of telomerase reverse transcriptase mutation and expression, telomerase activity and telomere length across human cancer cell lines cultured in vitro[J]. Exp Cell Res, 2020, 396(1): 112298. DOI: 10.1016/j.yexcr.2020.112298.
|
[16] |
HAYASHI Y, FUJITA K, MATSUZAKI K, et al. Clinical significance of hotspot mutation analysis of urinary cell-free DNA in urothelial bladder cancer[J]. Front Oncol, 2020, 10: 755. DOI: 10.3389/fonc.2020.00755.
|